skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Gain a deeper understanding of the implications of the Regenerative Medicine Advanced Therapies (RMAT) designation and the significance of its support and advancement by the FDA in this webinar recording, "RMAT Designation – Impact on Regenerative Medicine Sector".

Held in partnership with the Alliance for Regenerative Medicine (ARM), experts from both ARM and Informa Pharma Intelligence explored the RMAT designation and its implications.

In this recording You will gain insight into:

  • How the RMAT designation supports delivery of safe and effective gene and cell therapies to patients in need
  • How RMAT compares with other accelerated approval programs available to product sponsors
  • How the FDA supports and views the RM/AT sector


Read also

  • Biomedtracker: see the drug development process through anal...

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topics Coronavirus

  • Biomedtracker: see the drug development process through anal...

    Biomedtracker Potential Pivots in 2020

    In this infographic, we provide insight into key trials that are expecting developments in the approval process.

    Topics

  • Biomedtracker: see the drug development process through anal...

    2020 Early Outlook Webinar

    By Michael Haydock

    Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.

    Topics FDA

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: